S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:UNCY

Unicycive Therapeutics (UNCY) Stock Price, News & Analysis

$1.38
-0.08 (-5.48%)
(As of 03/28/2024 ET)
Today's Range
$1.38
$1.48
50-Day Range
$0.83
$1.79
52-Week Range
$0.47
$2.29
Volume
171,779 shs
Average Volume
358,717 shs
Market Capitalization
$47.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.30

Unicycive Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
501.4% Upside
$8.30 Price Target
Short Interest
Healthy
0.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Unicycive Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.62) to ($0.54) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.18 out of 5 stars

Medical Sector

544th out of 939 stocks

Pharmaceutical Preparations Industry

260th out of 444 stocks

UNCY stock logo

About Unicycive Therapeutics Stock (NASDAQ:UNCY)

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

UNCY Stock Price History

UNCY Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Unicycive Announces $50 Million Private Placement
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
See More Headlines
Receive UNCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unicycive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
3/29/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:UNCY
Fax
N/A
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.30
High Stock Price Target
$24.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+501.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-18,060,000.00
Pretax Margin
-4,159.11%

Debt

Sales & Book Value

Annual Sales
$950,000.00
Book Value
($0.03) per share

Miscellaneous

Free Float
20,157,000
Market Cap
$47.96 million
Optionable
Not Optionable
Beta
2.69
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Shalabh K. Gupta M.D. (Age 51)
    MPA, Founder, Chairman, CEO & President
    Comp: $1.46M
  • Dr. Pramod Gupta Ph.D. (Age 64)
    Executive Vice President of Pharmaceutical & Business Operations
    Comp: $779.18k
  • Mr. Douglas Jermasek M.B.A. (Age 63)
    Executive Vice President of Corporate Strategy
    Comp: $430.81k
  • Mr. John W. Townsend CPA (Age 62)
    Chief Financial Officer
    Comp: $197.86k

UNCY Stock Analysis - Frequently Asked Questions

Should I buy or sell Unicycive Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Unicycive Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" UNCY shares.
View UNCY analyst ratings
or view top-rated stocks.

What is Unicycive Therapeutics' stock price target for 2024?

5 analysts have issued 1-year price objectives for Unicycive Therapeutics' shares. Their UNCY share price targets range from $3.00 to $24.00. On average, they anticipate the company's stock price to reach $8.30 in the next year. This suggests a possible upside of 501.4% from the stock's current price.
View analysts price targets for UNCY
or view top-rated stocks among Wall Street analysts.

How have UNCY shares performed in 2024?

Unicycive Therapeutics' stock was trading at $0.8677 at the beginning of 2024. Since then, UNCY stock has increased by 59.0% and is now trading at $1.38.
View the best growth stocks for 2024 here
.

Are investors shorting Unicycive Therapeutics?

Unicycive Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 56,700 shares, an increase of 62.0% from the February 29th total of 35,000 shares. Based on an average daily volume of 347,600 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.2% of the shares of the company are short sold.
View Unicycive Therapeutics' Short Interest
.

When is Unicycive Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our UNCY earnings forecast
.

How were Unicycive Therapeutics' earnings last quarter?

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) posted its quarterly earnings data on Thursday, March, 28th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02.

When did Unicycive Therapeutics IPO?

Unicycive Therapeutics (UNCY) raised $25 million in an initial public offering on Tuesday, July 13th 2021. The company issued 4,600,000 shares at a price of $5.00-$6.00 per share. Roth Capital Partners served as the underwriter for the IPO and EF Hutton (formerly Kingswood Capital Markets) was co-manager.

Who are Unicycive Therapeutics' major shareholders?

Unicycive Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Nantahala Capital Management LLC (9.89%), BVF Inc. IL (6.09%) and Citadel Advisors LLC (0.10%).
View institutional ownership trends
.

How do I buy shares of Unicycive Therapeutics?

Shares of UNCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:UNCY) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners